Drug Profile
Natural killer cell therapy - CellProtect Nordic Pharmaceuticals
Alternative Names: CellProtectLatest Information Update: 10 Oct 2021
Price :
$50
*
At a glance
- Originator Avaris
- Developer Avaris; CellProtect Nordic Pharmaceuticals; Karolinska Institute; Sanofi
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple myeloma
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 01 Jul 2021 Phase-II clinical trials in Multiple myeloma (Combination therapy, First-line therapy, In adults, In the elderly) in Sweden (IV) (NCT04558931)
- 24 Sep 2020 NCT04558931: Update only, added FET for planned P-II trial, sent THES to replace MoA-Cell-replacements with Natural-killer-cell-replacements
- 22 Sep 2020 Karolinska Institutet in collaboration with Sanofi plans a phase II trial for Multiple myeloma (Combination therapy, First-line therapy, In adults, In the elderly) in Sweden (IV) in October 2020 (NCT04558931)